基于风险的心力衰竭一级预防:美国心脏协会科学声明
该科学声明指出心力衰竭(HF)疾病负担沉重,需优先推进一级预防;2022年AHA/ACC/HFSA指南首次推荐多变量风险方程评估新发HF风险,AHA新开发的PREVENT方程可单独预测HF。声明提出实施PREVENT-HF方程、利用生物标志物和超声心动图再分类及定义治疗特异性风险阈值等策略。
要点
- 2022年AHA/ACC/HFSA指南首次推荐多变量风险方程评估新发HF风险。
- PREVENT方程可单独预测新发HF,并将HF纳入总心血管病预测。
- 实施PREVENT-HF方程、靶向使用利钠肽和超声心动图、定义治疗特异性阈值。
核心结论
- 基于风险的心力衰竭一级预防需要实施PREVENT-HF方程、靶向使用心脏生物标志物和超声心动图进行风险再分类和早期检测,并定义纳入净获益和成本效益的治疗特异性风险阈值。
研究设计与样本
- 美国心脏协会科学声明,综述当前证据并定义公平预防策略,提出基于风险的一级预防实施策略。
主要发现
- 2022年AHA/ACC/HFSA HF指南首次推荐多变量风险方程评估新发HF风险。
- AHA开发的PREVENT方程可单独预测新发HF,并将HF纳入总心血管病预测。
- HF风险的主要表型为心血管-肾脏-代谢综合征。
- 钠-葡萄糖协同转运蛋白2抑制剂等新型疗法可预防新发HF并靶向多个心血管-肾脏-代谢轴。
关键数值与推荐
- 2022年AHA/ACC/HFSA HF指南首次推荐多变量风险方程评估新发HF风险。
- PREVENT方程可单独预测新发HF,并将HF纳入总心血管病预测。
- 实施PREVENT-HF方程、靶向使用利钠肽和超声心动图进行风险再分类和早期检测pre-HF。
- 定义纳入净获益和成本效益的治疗特异性风险阈值。
临床怎么用
- 在临床实践中实施PREVENT-HF方程评估新发HF风险。
- 靶向使用利钠肽和超声心动图进行风险再分类和早期检测pre-HF。
- 定义并应用治疗特异性风险阈值,纳入净获益和成本效益。
局限性
- 基于风险的心力衰竭预防方法仍处于起步阶段。
- 基于风险预防的概念已建立数十年,但迄今仅对动脉粥样硬化性心血管疾病预防进行了操作化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to prioritize its primary prevention. Whereas a risk-based approach for HF prevention remains in its infancy, several key opportunities exist to actualize this paradigm in clinical practice. First, the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America HF guidelines provided recommendations, for the first time, on the clinical utility of multivariable risk equations to estimate risk of incident HF. Second, the American Heart Association recently developed the PREVENT (Predicting Risk of Cardiovascular Disease Events) equations, which not only enable prediction of incident HF separately, but also include HF in the prediction of total cardiovascular disease. Third, the predominant phenotype of HF risk has emerged as the cardiovascular-kidney-metabolic syndrome. Fourth, the emergence of novel therapies that prevent incident HF (eg, sodium-glucose cotransporter-2 inhibitors) and target multiple cardiovascular-kidney-metabolic axes demonstrate growing potential for risk-based interventions. Whereas the concept of risk-based prevention has been established for decades, it has only been operationalized for atherosclerotic cardiovascular disease prevention to date. Translating these opportunities into a conceptual framework of risk-based primary prevention of HF requires implementation of PREVENT-HF (Predicting Risk of Cardiovascular Disease Events-Heart Failure) equations, targeted use of cardiac biomarkers (eg, natriuretic peptides) and echocardiography for risk reclassification and earlier detection of pre-HF, and definition of therapy-specific risk thresholds that incorporate net benefit and cost-effectiveness. This scientific statement reviews the current evidence for accurate risk prediction, defines strategies for equitable prevention, and proposes potential strategies for the successful implementation of risk-based primary prevention of HF.
引用
- Khan, Breathett, Braun, et al. Risk-Based Primary Prevention of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2025. PMID: 40235437. doi:10.1161/CIR.0000000000001307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。